Announced Date: 2025-07-30 (JULY 30, 2025)
Asset Name: SYH2086
Licensor: CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (CSPC) (Headquarter Shijiazhuang City, Hebei Province, China)
Licensee (Buyer): Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) (Madrigal) (Headquarter, West Conshohocken, PA 19428, USA)
Asset Target: Oral glucagon-like peptide-1 (GLP-1) receptor agonist
Asset Modality: Small Molecule
Current Stage: preclinical ;
Madrigal plans to initiate clinical development in the first half of 2026.
Scope of Authority:
CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086.
CSPC may develop and commercialize other oral GLP-1 agonists in China subject to certain conditions.
Deal Detail:
Upfront payment of $120 million
Milestone payments up to $2 billion (1.955 billion) (if certain development, regulatory and commercial milestones are achieved)
Royalties on net sales, two digital
Total 2.075 billion plus
The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance.
Link:
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
